Top Markets
Coin of the day
TaiGen Biopharmaceuticals Holdings Limited TaiGen Biopharmaceuticals Holdings Limited

TaiGen Biopharmaceuticals Holdings Limited

4157
Rank in Stocks #18388
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm... TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
Share Price
$0.28078542
Market Cap
$199.87M
Change (1 day)
-0.34%
Change (1 year)
-10.19%
Country
TW
Trade TaiGen Biopharmaceuticals Holdings Limited (4157)

Category

P/B ratio for TaiGen Biopharmaceuticals Holdings Limited (4157)
P/B ratio as of 2026 TTM: 0
According to TaiGen Biopharmaceuticals Holdings Limited latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for TaiGen Biopharmaceuticals Holdings Limited from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.828 -
US
7.5116 -
NL
8.2199 -
US
3.9942 -
AU
- -
CH